Elan Corp, plc (ADR) (NYSE:ELN.DL)

CAPS Rating: No stars

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.


Player Avatar rainmaker59 (38.24) Submitted: 11/11/2009 9:29:44 PM : Outperform Start Price: $6.32 ELN.DL Score: +121.53

Rulebreaker pick of Jan. 2009. All debt is related to massive R&D expenses. Leading edge of RX for Crohn's, MS and Alzheimer's.

Member Avatar wanttobelieve (< 20) Submitted: 12/15/2009 12:03:48 AM
Recs: 0

They are a poorly run company that cannot even produce their own drugs

Featured Broker Partners